<DOC>
	<DOCNO>NCT00391066</DOCNO>
	<brief_summary>This randomize ( 1:1 ) , open-label , multicenter , active-controlled study patient previously treat CD23+ CD20+ relapse CLL . Patients receive treatment either lumiliximab combination FCR FCR alone .</brief_summary>
	<brief_title>Lumiliximab With Fludarabine , Cyclophosphamide , Rituximab ( FCR ) Versus FCR Alone Subjects With Relapsed Chronic Lymphocytic Leukemia ( CLL )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Signed , write ECapproved informed consent form . Diagnosis relapse CD23+ CD20+ B cell CLL define NCI WG guideline . Subjects receive least 1 2 prior single agent combination treatment CLL . Rai Stage III IV ( Binet Stage C ) , Rai Stage I II ( Binet Stage A B ) determine disease progression evidence rapid double peripheral lymphocyte count , progressive lymphadenopathy , progressive splenomegaly , B symptom ( Staging Criteria Modified Rai ) . WHO Performance Status less equal 2 . Age great equal 18 year . Male female subject reproductive potential must agree follow accepted birth control method treatment 12 month completion treatment . Acceptable liver function : bilirubin le equal 2.0 mg/dL ( 26 Âµmol/L ) ; AST ALT less equal 2 time upper limit normal . Acceptable hematologic status : platelet count great equal 50 x 10^9/L unsupported transfusion ; ANC great equal 1 x 10^9/L . Acceptable renal function : creatinine clearance calculate accord formula Cockcroft Gault &gt; 50 mL/min ; serum creatinine less equal 1.5 time upper limit normal . Subjects refractory follow combination therapy : purine analogue + R , purine analogue + C , purine analogue + CR . Refractory define achieve least PR minimum duration 6 month determine treat physician . Purine analogues include fludarabine , pentostatin cladribine . Radiotherapy , radioimmunotherapy , biological therapy , chemotherapy , investigational therapy within 4 week prior Study Day 1 . Previous exposure lumiliximab antiCD23 antibody . Prior autologous allogeneic BMT hematopoetic stem cell transplant . Known infection HIV , hepatitis B , hepatitis C. Although test hepatitis B hepatitis C mandatory , consider subject consider high risk hepatitis B hepatitis C infection endemic area . Subjects serological evidence current past hepatitis B hepatitis C exposure exclude unless serological finding clearly due vaccination . Uncontrolled diabetes mellitus . Uncontrolled hypertension . Transformation aggressive Bcell malignancy ( e.g. , large B cell lymphoma , Richter 's Syndrome , PLL ) . Secondary malignancy require active treatment ( except hormonal therapy ) . Any medical condition would require longterm use ( &gt; 1 month ) systemic corticosteroid study treatment . However , steroid use less equal 1 month permissible study . Any serious nonmalignant disease laboratory abnormality , opinion Investigator and/or Sponsor would compromise protocol objective . Active uncontrolled bacterial , viral , fungal infection . New York Heart Association Class III IV cardiac disease , myocardial infarction within past 6 month prior Study Day 1 , unstable arrhythmia , evidence ischemia ECG within 30 day prior Study Day 1 . Seizure disorder require anticonvulsant therapy . Severe chronic obstructive pulmonary disease hypoxemia . Major surgery , diagnostic surgery , within 4 week prior Study Day 1 . Clinically active autoimmune disease . History fludarabineinduced autoimmune cytopenia ( judged Investigator ) Coombspositive haemolytic anemia . Pregnant currently breastfeed .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>CD23+/CD20+ B-cell CLL</keyword>
	<keyword>CLL</keyword>
</DOC>